Cerebellar ataxia is a heterogeneous genetic disorder characterized by inability to control balance and coordination. Roughly 50% of patients remain undiagnosed despite advanced genomic testing.^[@R1][@R2][@R4]^The most common genetic ataxias, as well as several rarer forms, are caused by nucleotide repeat expansions, which typically require targeted non--sequence-based testing to identify.^[@R5][@R6][@R8]^

Recent studies identified a recessive intronic (AAGGG) repeat expansion in replication factor C subunit 1 (*RFC1*) related to cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS) in Australia and the United Kingdom.^[@R9],[@R10]^ In addition, this expansion may be responsible for up to 22% (33/150) of sporadic cerebellar ataxia and 63% (32/51) of ataxia associated with sensory neuropathy.^[@R9]^ Similarly, a dominant pathologic pentanucleotide (ATTTC) repeat insertion was identified within a normal (ATTTT) tandem repeat element in the intronic 5′ untranslated region of the disabled adaptor protein 1 (*DAB1*) gene causing spinocerebellar ataxia type 37 (SCA37) in patients from the southern Iberian Peninsula.^[@R11]^

To address the frequency of these repeat expansion disorders in North America, we assessed a large cohort of 596 patients from the United States with unidentified cerebellar ataxia. We identified biallelic *RFC1* expansion in 1.5% (n = 9) and found no patients with a pathogenic *DAB1* expansion. We further tested 2 additional cohorts from different centers (the larger of which consisted of approximately one-third samples from patients in Canada, with the remainder from the United States) and identified *RFC1-*mediated ataxia cases in 5.6% (17/302) and 23% (3/13), respectively, for a total prevalence of 3.2% (29/911).

Methods {#s1}
=======

Standard protocol approvals, registrations, and patient consents {#s1-1}
----------------------------------------------------------------

Patients were enrolled at the University of California, Los Angeles (UCLA) Ataxia Center, clinically assessed for acquired causes of ataxia, and then considered for genetic causes.^[@R2]^ Only patients with negative testing for the common genetic ataxias (SCA1, SCA2, SCA3, SCA6, SCA7, and Friedreich ataxia) were included in this study. The majority (∼ two-thirds) were adult and sporadic onset. All patients consented for DNA collection for genetic analysis. Peripheral blood was collected from patients, and DNA was then isolated and purified using the Gentra Puregene Blood Kit (Qiagen) for genetic testing. The study methods used were approved by the UCLA Institutional Review Board. Additional DNA samples from 302 patients enrolled at the University of Chicago and 13 patients enrolled at the Brigham and Women\'s Hospital under institutional review board-approved procedures with identical inclusion criteria were subsequently tested as well. For the purpose of assessing disease prevalence, only probands from affected families were included in this study, and all pathogenic repeat expansions were confirmed in additional affected family members when available.

Repeat expansion testing {#s1-2}
------------------------

### *RFC1* gene repeat expansion analysis {#s1-2-1}

Fluorescent repeat-primed PCR (RP-PCR) was performed to detect *RFC1* pathogenic (AAGGG)~n~ alleles using previously published primers^[@R9],[@R10]^ with an optimized touchdown PCR protocol and Qiagen HotStarTaq. One primer set included the forward 5′FAM-ACTGACAGTGTTTTTGCCTGT-3′ primer, the anchor 5′-CAGGAAACAGCTATGACC-3′ primer, and the repeat 5′-CAGGAAACAGCTATGACCAAGGGAAGGGAAGGGAAGGGAAGGG-3′ primer that identifies the (AAGGG) repeats. A second primer set included the forward 5′FAM-TCAAGTGATACTCCAGCTACACCGT-3′ primer, the anchor 5′-CAGGAAACAGCTATGACC-3′ primer, and 3 repeat primers that identify the (AAGGG) repeats 5′-CAGGAAACAGCTATGACCAACAGAGCAAGACTCTGTTTCAAAAAAGGGAAGGGAAGGGAAGGGAA-3′, 5′-CAGGAAACAGCTATGACCAACAGAGCAAGACTCTGTTTCAAAAAGGGAAGGGAAGGGAAGGGAA-3′, and 5′-CAGGAAACAGCTATGACCAACAGAGCAAGACTCTGTTTCAAAAGGGAAGGGAAGGGAAGGGAA-3′. Fragment length analysis was performed using an Applied Biosystems 3730xl DNA Analyzer with Peak Scanner software (v. 2.0). To determine whether the genotype of samples with positive RP-PCR results was heterozygous or biallelic, standard PCR was performed using published primers,^[@R9]^ forward 5′-TCAAGTGATACTCCAGCTACACCGTTGC-3′ primer and the reverse 5′ GTGGGAGACAGGCCAATCACTTCAG-3′ primer. Observation of a band at or near 348 bp (wild-type size) corresponding to repeat sizes of less than approximately 60 repeats (approximately 650 bp) identified patients as heterozygotes. As an internal control to prevent false positives, standard PCR was also performed simultaneously on the same sample with primers designed to amplify a 282-bp band from the *SPG11* gene (figure e-1, [links.lww.com/NXG/A266](http://links.lww.com/NXG/A266)).

For a proportion of samples at the University of Chicago, 3 separate reactions each using 100 ng of genomic DNA were performed to confirm the existence of a true biallelic (AAGGG) repeat expansion (figure e-2, [links.lww.com/NXG/A267](http://links.lww.com/NXG/A267)). First, a flanking PCR was performed using primers that surrounded the RFC1 region of interest. The flanking primers included a labeled forward primer^[@R9]^ (5′-/56-FAM/ACTGACAGTGTTTTTGCCTGT-3′) (10 μm) and a reverse primer^[@R9]^ (5′-GGCTGAGGCAGGAGATTCAC-3′) (10 μm). Second, RP‐PCR was performed to detect individual nonpathogenic (AAAAG) motifs. The primers for the (AAAAG) RP-PCR included the same forward primer as the flanking reaction, an M13 anchor primer (5′-CAGGAAACAGCTATGACC-3′) (10 μm) and an (AAAAG) specific primer (5′-CAGGAAACAGCTATGACC_AAAAGAAAAGAAAAGAAAAGAAAAG-3′) (1 μm). Both the flanking and (AAAAG) RP-PCR products were amplified using the Takara LA PCR kit in combination with a touchdown PCR. Third, to detect individual pathogenic (AAGGG) motifs, a PCR reaction was performed using the same forward primer as the flanking, the M13 anchor primer, and an (AAGGG) specific primer^[@R9]^ (5′-CAGGAAACAGCTATGACC_AAGGGAAGGGAAGGGAAGGGAAGGG-3′). To obtain full amplification of the expanded (AAGGG) motif, the Qiagen HotStarTaq chemistry was used with 400 μm of deoxyribonucleotide triphosphates using a standard PCR. All 3 products were loaded on an ABI3730xl DNA analyzer after denaturing with a 5% GS500 Rox/formamide mixture and subsequently analyzed using GeneMarker v2.6.0 (SoftGenetics Inc.).

To validate the assays performed at the different centers, a proportion of samples (\>50%) determined to have heterozygous or biallelic AAGGG expansions were assessed at least 2 times by both expansion RP-PCR testing and standard PCR genotyping in 2 separate laboratories.

### *DAB1* gene repeat expansion analysis {#s1-2-2}

RP-PCR was performed to detect expansion of the normal (ATTTT) *DAB1* repeat region and for detection of the pathogenic (ATTTC)~n~ insertion using published primers.^[@R11],[@R12]^ Fragment length analysis was performed as described above.

Data availability {#s1-3}
-----------------

The data sets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.

Results {#s2}
=======

We examined the prevalence of repeat expansions in *RFC1* and *DAB1* in a large cohort from the tertiary referral Ataxia Center at UCLA. The demographics of this 596 subject cohort are described in [table 1](#T1){ref-type="table"}. Average age was 55 years, 50% of the patients were female, and 66% were white, non-Hispanic. The most common phenotypes were spinocerebellar ataxia (26.5%), pure cerebellar ataxia (21.6%), and multiple system atrophy (17.4%). To assess for the presence of pathogenic (AAGGG) repeat expansions in *RFC1*, fluorescent repeat-primed fragment analysis was performed and identified at least 1 expansion in 50 of 596 patients (8.4%, [figure 1](#F1){ref-type="fig"} and figure e-1, [links.lww.com/NXG/A266](http://links.lww.com/NXG/A266)). Standard PCR was used to genotype subjects for the presence of a heterozygous or a pathogenic biallelic expansion. Nine subjects (1.5%) were found with biallelic expansions. Of these patients, 3 subjects presented clinically with CANVAS (33%, 100% of phenotype), 5 had cerebellar ataxia with neuropathy (56%, 12% of phenotype), and 1 had spinocerebellar ataxia (11%, 0.6% of phenotype).

###### 

Patient demographics

![](NG2019012450t1)

![RFC1 expansion analysis\
Representative RP-PCR results from a patient with disease due to (A) biallelic expanded (AAGGG) pathogenic alleles or a control individual (B) with wild-type alleles. Samples with RP-PCR evidence of an expanded *RFC1* allele were genotyped by standard PCR for biallelic expansion (C). Standard PCR allows categorization of individuals as biallelic with pathogenic expansions (no band, lanes 1-4), heterozygous wild-type (348 bp band, arrow, lanes 5-8), heterozygous with a non-pathogenic polymorphic expansion (variable sized bands, lanes 9-11), or wild-type with one or more non-pathogenic polymorphic expansion(s) (variable sized band(s), lanes 12-14). + = biallelic control; − = wild-type control; M = marker; *RFC1* = replication factor C subunit 1.](NG2019012450f1){#F1}

To validate these findings, we tested 2 additional cohorts from centers in different regions of the United States, the University of Chicago (UC) and Brigham and Women\'s Hospital affiliated with Harvard Medical School. Demographics were similar to the UCLA cohort ([table 1](#T1){ref-type="table"}). The larger UC cohort, consisting of both sporadic and familial cases with roughly one-third of subjects originating from Canada, showed heterozygous expansions in 20 individuals (6.6%) and pathogenic biallelic expansion in 17 patients (5.6%) (figure e-2, [links.lww.com/NXG/A267](http://links.lww.com/NXG/A267)). Four subjects had CANVAS (24%, 57% of phenotype), 7 had cerebellar ataxia with neuropathy (41%, 39% of phenotype), 4 had pure cerebellar ataxia (23.5%, 6.5% of phenotype), and 2 had spinocerebellar ataxia (12%, 1.4% of phenotype). In the smaller Harvard cohort, 1 individual showed heterozygous expansion (7.7%), and 3 of 13 patients (23%) had pathogenic biallelic expansions. Two of these had cerebellar ataxia with neuropathy (67%, 50% of phenotype), while 1 had CANVAS (33%, 100% of phenotype). Collectively, 62 individuals were found with heterozygous expansion (6.8%, 62/911, [table 2](#T2){ref-type="table"}), and 29 of 911 subjects showed pathogenic biallelic expansions across all cohorts for a total prevalence of 3.2% (29/911, [table 3](#T3){ref-type="table"}). Of the biallelic cases, the majority of the patients were white (24/29, 83%), 1 patient was Hispanic (1/29, 3.4%), and the race/ethnicity of 5 patients was not reported (17%). Twelve of the cases showed sporadic onset (41%). In total, 8 subjects had CANVAS (28%, 73% of phenotype), 14 had cerebellar ataxia with neuropathy (48%, 22% of phenotype), 4 had pure cerebellar ataxia (14%, 2.1% of phenotype), and 3 had spinocerebellar ataxia (10%, 1.0% of phenotype).

###### 

Demographics of patients with heterozygous expansions in the *RFC1* gene
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###### 

Demographics of patients with biallelic expansions in the *RFC1* gene

![](NG2019012450t3)

For *DAB1* repeat expansion analysis, 83/596 (13.9%) subjects showed an expanded ATTTT allele by RP-PCR analysis; however, none of these patients possessed the pathogenic ATTTC insertion, indicating that no patients within the cohort had SCA37.

Discussion {#s3}
==========

Overall, in a large undiagnosed ataxia cohort of 911 patients from 3 tertiary referral centers in the United States, biallelic pathogenic (AAGGG) repeat expansions in *RFC1* were observed in 3.2% (n = 29, 95% CI 2.0%--4.3%) of patients from the United States (25/29, 86%) and Canada (4/29, 14%). The observation that the majority of cases (24/24, 100%, [table 3](#T3){ref-type="table"}), where ethnicity was known, were white of European ancestry is consistent with previous reports.^[@R9],[@R10]^ Of the heterozygotes with race and ethnicity data available, 96% (47/49, [table 2](#T2){ref-type="table"}) were of white ancestry, and overall, single or biallelic expansions were detected in 7.1% and 3.6%, respectively, of the total white population surveyed in this study. The high rate of heterozygosity (6.8%) in our cohort is notable but is similar to 1 previous study, which calculated an allele frequency of 4% in control populations of 69 and 133 individuals based on haplotype in next-generation sequencing data sets,^[@R10]^ although another study found a frequency of 0.7% in a cohort of 304 healthy controls using RP-PCR.^[@R9]^ Although our methods cannot accurately size larger repeats, standard PCR analysis indicated that under the conditions of our AAGGG RP-PCR assay, we were able to detect small expansions up to 60 repeats above wild type (∼650 bp, [figure 1](#F1){ref-type="fig"} and figure e-1, [links.lww.com/NXG/A266](http://links.lww.com/NXG/A266)), and therefore, we suspect that our high rate of detection may be due, in part, to the detection of confounding mildly expanded alleles below the estimated 400 repeat margin of pathogenicity^[@R9]^ ([figure 1](#F1){ref-type="fig"} and figure e-1, [links.lww.com/NXG/A266](http://links.lww.com/NXG/A266)). It is interesting to note that small AAGGG expansions have not previously been reported in patients or controls,^[@R9],[@R10]^ and because all subjects tested presented with some form of cerebellar ataxia, we cannot exclude the possibility that expanded AAGGG repeats may contribute to the development of cerebellar ataxia in some heterozygous individuals. We also cannot rule out a contribution of false-positive detection of other small polymorphic nonpathogenic non-AAGGG repeats^[@R9]^ in some heterozygous individuals. We did confirm all biallelic subjects with RP-PCR and standard PCR in at least 2 experiments each across 2 separate laboratories and further determined that none of these individuals harbored the most common nonpathogenic expanded repeat, AAAAG^[@R9]^ (data not shown).

In addition, the pathogenic (ATTTC) repeat in the *DAB1* gene, causative for SCA37, was not observed in our large undiagnosed ataxia cohort of 596 individuals of mostly white, non-Hispanic ancestry, consistent with the observation of a founder effect in the Iberian Peninsula^[@R11],[@R13]^ and suggesting that although this disorder should be considered in that population, it is likely extremely rare in the United States. Although no pathogenic ATTTC insertions were found, it is possible that extremely large repeats of ATTTT flanking a pathogenic ATTTC insertion might prevent amplification of products from the RP-PCR, so false negatives cannot be ruled out in this study, although this has not been commonly observed in published reports.^[@R11],[@R12]^

Consistent with previous reports, our study identified biallelic *RFC1* expansions in a high percentage of patients with CANVAS (n = 8, 73%) and cerebellar ataxia with neuropathy^[@R9]^ (n = 14, 22%). Although we do not have electrophysiologic data on all subjects, of the biallelic patients identified, all appeared to have a large fiber neuropathy (data not shown), which would be an important focus for further clinical investigation. In addition, we also observed biallelic expansion in a notable percentage of patients with pure cerebellar ataxia (n = 4, 2.1%) and generalized spinocerebellar ataxia (n = 3, 1.0%), a frequency on par with the majority of rare ataxic disorders identifiable by clinical sequencing.^[@R2]^ Based on this study, the presence of neuropathy confers a 20.1% absolute benefit to testing (95% CI 9.7%--30.6%) over pure cerebellar ataxia alone, and the presence of both neuropathy and vestibulopathy further increases this to 70.6% (95% CI 44.2%--97.0%), with biallelic *RFC1* expansions anticipated in 1 of every 5.0 (95% CI 3.3--10.3) and 1 of every 1.4 (95% CI 1.0--2.3) patients tested, respectively. Taken together, these results suggest that *RFC1* expansion testing is high yield in cases of CANVAS and cerebellar ataxia with neuropathy but should also be considered in the genetic workup of patients with undiagnosed pure cerebellar and spinocerebellar ataxia.

Editorial, page e436

The authors thank all the patients and their families for their participation in this study.

Study funding
=============

This work was supported by the National Institute for Neurological Disorders and Stroke \[R01NS082094 to BLF\]. BLF acknowledges support through donations to the University of California by the Rochester Ataxia Foundation. PJL was supported by the Vincent Chiodo Foundation. CMG and VK acknowledge support from the National Ataxia Foundation and the Brigham Research Institute.

Disclosure
==========

All authors declare that there is no conflict of interest. Go to [Neurology.org/NG](https://ng.neurology.org/content/6/3/e440/tab-article-info) for full disclosures.

Publication history
===================

This manuscript was previously posted on bioRxiv: doi: 10.1101/790006. Received by *Neurology: Genetics* November 7, 2019. Accepted in final form March 15, 2020.

CANVAS

:   cerebellar ataxia, neuropathy, and vestibular areflexia syndrome

*DAB1*

:   Disabled Adaptor Protein 1

*RFC1*

:   replication factor C subunit 1

SCA37

:   spinocerebellar ataxia type 37
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